May 10th 2022
Alexander I. Spira, MD, PhD, FACP, research institute director with Virginia Cancer Specialists Research Institute, discusses the examination of RTX-240 in a phase 1 trial (NCT04372706) with solid tumors, presented recently at the 2022 AACR Annual Meeting.
April 15th 2022
Already, NG-641 has shown encouraging preliminary safety and tolerability results in the ongoing phase 1a dose-escalation STAR trial (NCT04053283), which is a first-in-human study for the gene therapy.
April 14th 2022
While the lower IV dose was generally well-tolerated, the higher dose yielded cases of serious cytokine release syndrome.
April 13th 2022
The phase 1, investigator-initiated trial continues to recruit participants with B-ALL.
April 12th 2022
The novel regimen from BioNTech demonstrated encouraging results in patients with testicular or ovarian cancer.
April 11th 2022
AFM13 is currently also being evaluated on its own in lymphoma in a phase 2 registrational study.
April 9th 2022
The first in-human phase 1 clinical trial is being conducted in Japan.
July 21st 2021
The founder and chief executive officer of SQZ Biotech discussed the potential of their APC platform to treat a variety of tumors.